China's pharmaceutical industry is in a new initial stage


Release time:

2017-12-10

In the first three quarters, the growth of the main business exceeded the "13th Five-Year Plan" development goal.

A few days ago, the Ministry of Industry and Information Technology released the economic operation data of the pharmaceutical industry in the first three quarters. From January to September, the added value of the pharmaceutical industry above designated size increased by 11.6 year-on-year, and the growth rate increased by 1.2 percentage points from the same period last year, which was 4.9 percentage points higher than the overall growth rate of the national industry, and ranked in the forefront of the entire industry. The main business income of enterprises above the scale of the pharmaceutical industry reached 2293.645 billion billion yuan, an increase of 11.7 over the same period last year, and the growth rate was 1.6 percentage points higher than that of the same period last year.

Zhu Hongren, executive vice president and chairman of the China Entrepreneurs Federation, recently pointed out at the "2017 China Pharmaceutical and Health Industry Development Summit" hosted by the China Pharmaceutical Industry Information Center that since 2014, my country's pharmaceutical industry has contributed to the growth of the entire industry. The rate continues to rise, and its contribution rate has been higher than the proportion of the pharmaceutical industry's GDP in GDP. In the first three quarters of this year, the growth rate of the main business of the pharmaceutical industry exceeded the "13th Five-Year" development plan for the pharmaceutical industry.

 

    The pharmaceutical industry is developing steadily.

This year is the first year after the release of the "13th Five-Year" development plan for the pharmaceutical industry. According to the planning target, during the 13th Five Year Plan period, the annual growth rate of the main business of the pharmaceutical industry will reach more than 10%, and the growth rate of the main business of the pharmaceutical industry in the first three quarters of this year will exceed the target by 1.7 percentage points. At the same time, enterprises above the scale of the pharmaceutical industry achieved a total profit of 255.726 billion billion yuan, an increase of 17.5 percent over the same period last year, the profit margin of their main business income reached 11.2 percent, the area of enterprise losses narrowed by 0.4 percentage points, and the amount of losses fell by 12.9 percent compared with the same period last year.

Hua Xuewei, deputy director of the China Pharmaceutical Industry Information Center, believes that the pharmaceutical industry is now in a new era and a new initial stage. The national health China strategy has moved from deployment to implementation, and the health cause has brought tangible benefits to the people. The six major projects of the "Pharmaceutical Industry Development Planning Guide", including the innovation capability improvement project, the product quality upgrade project, and the drug supply guarantee project, describe the blueprint for the development of the pharmaceutical industry. The continuous expansion of the connotation of the traditional medicine and health industry has brought new development opportunities. In particular, the "Belt and Road" initiative has brought new opportunities for the expansion of the pharmaceutical industry.

In recent years, the state has paid special attention to the development of the pharmaceutical industry, the promotion and leading role of the policy level has been significantly strengthened, and the number of policies related to the pharmaceutical industry has doubled year by year. According to statistics, in 2010, China issued only 45 policies related to the pharmaceutical industry, reaching 194 in 2016, and the number of policies issued in the first half of this year exceeded that of the whole of last year. At the same time, the specifications of the pharmaceutical industry policy are also improving. In 2011, the State Council issued only 7 policies related to the pharmaceutical industry, 21 in 2016 and 15 in the first half of this year. Among these industrial policies, the proportion of macro policies is gradually increasing, indicating that the country's macro-control in the field of medicine and health is increasing.

Zhu Hongren pointed out that the current pharmaceutical industry is generally improving steadily. In addition to the steady growth of major economic indicators, there are many bright spots in technological innovation, organizational innovation and market innovation: in 2016, 128 Class 1 new drugs were approved for clinical use, 4 Class 1 new drugs were approved for listing, and the number of new drug registrations increased rapidly. Enterprise mergers and acquisitions are active, and the scale of domestic and foreign mergers and acquisitions is expected to achieve new breakthroughs this year, large enterprises to strengthen mergers and acquisitions to expand the scale, a large number of new drug research and development to get the support of equity investment funds, internationalization, to meet the advanced quality standards of Europe and the United States preparation enterprises increased, the scale of international mergers and acquisitions increased.

 

    Structural adjustment is still the main theme of development

In fact, the good results achieved by the pharmaceutical industry in the first three quarters of this year are not easy. Since 2015, the scale of China's pharmaceutical market has bid farewell to the double-digit growth that has lasted for many years. 2016 is the first year of the "13th Five-Year Plan". The growth rate of the pharmaceutical market has dropped to 8.1 year-on-year. The decline in growth rate is mainly due to the decline in drug sales in medical institutions and the tremendous pressure on the development of the pharmaceutical industry. Fortunately, with the gradual deepening of the "new medical reform" and the continuous advancement of the "strong grassroots" construction and the "hierarchical diagnosis and treatment" system, the proportion of the three major market terminals with urban medical institutions, retail pharmacies and primary medical care as the main body has begun to change. The proportion of pharmacies and primary medical care is expanding, and the proportion of urban medical institutions is shrinking. It is estimated that by 2021, the proportion of the three major terminals will be further adjusted to 59%, 15% and 26%.

"Structural adjustment is still the main theme of the development of the pharmaceutical industry. In the future, the development of different types of drugs in the pharmaceutical market will show different trends." Hua Xuewei said. Specifically, the current market size of chemical drugs is 966.2 billion yuan, 90% of which are generic drugs. The evaluation of the quality and efficacy consistency of generic drugs will change the competitive landscape. In the future, new drug research and development innovation will be a sharp weapon for market competition; the market size of Chinese patent medicines It is about 347.6 billion yuan, and the overall growth rate of the industry has slowed down, but the implementation of the "Chinese Medicine Law" will bring policy dividends to enterprises, in the future, innovative products and technologies will be used to achieve full coverage of service areas, and the core advantages of products will be found and verified in combination with big health. The biomedical market is 129.8 billion yuan, with a rapid growth rate, but there is still a big gap compared with the average growth rate of 25% in developed countries. There is huge room for development. In the future, the investment in biomedicine will continue and clinical applications will increase.

Zhu Hongren expressed the hope that the pharmaceutical industry will take advantage of the situation, seize the opportunity of industrial development, focus on technological innovation, and speed up the research and development of new drugs; focus on organizational innovation, speed up restructuring and integration, strict industry access, reduce new production capacity, increase industry concentration, and promote the concentration of resources to superior enterprises; focus on integration and innovation, speed up intelligent upgrading, promote quantitative integration, and support enterprises to innovate research and development means with information technology, improve the level of automation, digitization and intelligence of the production process, realize the automatic collection, management and traceability of quality data, focus on open innovation, speed up the global layout, based on the advantages of the API industry, implement the strategy of internationalization of preparations, and improve the added value of preparation exports.